Levormeloxifene
Jump to navigation
Jump to search
Clinical data | |
---|---|
Other names | Levomeloxifene; 6720-CDRI; NNC-460020 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C30H35NO3 |
Molar mass | 457.614 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Levormeloxifene (INN ; developmental code names 6720-CDRI, NNC-460020) is a selective estrogen receptor modulator (SERM) which was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss but did not complete development and hence was never marketed.[1] The development was stopped because of a high incidence of gynecological side effects during clinical trials.[2] Levormeloxifene is the levorotatory enantiomer of ormeloxifene, which, in contrast, has been marketed, though rather as a hormonal contraceptive.
See also
References
- ^ "Levormeloxifene - AdisInsight".
- ^ Ravn P, Nielsen TF, Christiansen C (2006). "What can be learned from the levormeloxifene experience?". Acta Obstet Gynecol Scand. 85 (2): 135–42. doi:10.1080/00016340500345691. PMID 16532904. S2CID 12872469.
External links
Categories:
- Articles with short description
- Short description matches Wikidata
- Articles with changed CASNo identifier
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs missing an ATC code
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Abandoned drugs
- Benzopyrans
- Ethers
- 1-Pyrrolidinyl compounds
- Selective estrogen receptor modulators
- All stub articles
- Genito-urinary system drug stubs